NASC (Nascent Pharma Holdings) Cyclically Adjusted Book per Share: $-9.96 (As of Sep. 2024)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Cyclically Adjusted Book per Share?

Nascent Pharma Holdings NASC 12 Cyclically Adjusted Book per Share is $-9.96 as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nascent Pharma Holdings's adjusted book value per share for the three months ended in Sep. 2024 was $-0.257. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-9.96 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-27), Nascent Pharma Holdings's current stock price is $0.0114. Nascent Pharma Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was $-9.96. Nascent Pharma Holdings's Cyclically Adjusted PB Ratio of today is .


Nascent Pharma Holdings  (OTCPK:NASC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nascent Pharma Holdings Cyclically Adjusted Book per Share Related Terms


Nascent Pharma Holdings Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Cyclically Adjusted Book per Share Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -5.60 -6.89 -9.53 -9.65

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.63 -9.65 -9.85 -9.92 -9.96

NASC vs ALID, CPMD, PLSH: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Pharma Holdings Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's Cyclically Adjusted PB Ratio falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nascent Pharma Holdings's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.257/315.3010*315.3010
=-0.257

Current CPI (Sep. 2024) = 315.3010.

Nascent Pharma Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.388 234.812 0.521
201503 2.061 236.119 2.752
201506 0.778 238.638 1.028
201509 5.370 237.945 7.116
201512 -0.031 236.525 -0.041
201603 0.000 238.132 0.000
201606 -6.563 241.018 -8.586
201609 -9.250 241.428 -12.080
201612 -19.344 241.432 -25.263
201703 -15.029 243.801 -19.437
201706 -25.139 244.955 -32.358
201709 -19.763 246.819 -25.246
201712 -39.480 246.524 -50.494
201803 -20.327 249.554 -25.682
201806 -32.519 251.989 -40.689
201809 -15.104 252.439 -18.865
201812 -10.908 251.233 -13.690
201903 -2.885 254.202 -3.578
201906 -2.742 256.143 -3.375
201909 6.329 256.759 7.772
201912 6.207 256.974 7.616
202003 0.634 258.115 0.774
202006 -2.610 257.797 -3.192
202009 -6.877 260.280 -8.331
202012 -88.030 260.474 -106.559
202103 -0.770 264.877 -0.917
202106 -2.285 271.696 -2.652
202109 0.037 274.310 0.043
202112 -8.122 278.802 -9.185
202203 0.221 287.504 0.242
202206 0.033 296.311 0.035
202209 -0.965 296.808 -1.025
202212 -1.259 296.797 -1.337
202303 -1.071 301.836 -1.119
202306 -1.345 305.109 -1.390
202309 -0.305 307.789 -0.312
202312 -0.282 306.746 -0.290
202403 -0.297 312.332 -0.300
202406 -0.233 314.175 -0.234
202409 -0.257 315.301 -0.257

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-9.96 mean?
Nascent Pharma Holdings (NASC) has a Cyclically Adjusted Book per Share of $-9.96 as of Sep. 2024. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Cyclically Adjusted Book per Share too high?
Nascent Pharma Holdings' current Cyclically Adjusted Book per Share is $-9.96. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Cyclically Adjusted Book per Share compare to ALID and CPMD?
Nascent Pharma Holdings' Cyclically Adjusted Book per Share of $-9.96 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Cyclically Adjusted Book per Share is $-9.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Cyclically Adjusted Book per Share of $-9.96. The current Cyclically Adjusted Book per Share is $-9.96. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Cyclically Adjusted Book per Share is $-9.96 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price